| VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study.Clin Infect Dis | PMID 36358012无 PMCID | 2023-Apr-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.Clin Infect Dis | PMID 36411267PMC10069855 | 2023-Apr-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open | PMID 37022687PMC10080377 | 2023-Apr-03 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials.JAMA Netw Open | PMID 37083668PMC10122174 | 2023-Apr-03 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.JAMA Netw Open | PMID 37099299PMC10536880 | 2023-Apr-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials.Pain | PMID 36066965PMC10026829 | 2023-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.J Clin Oncol | PMID 36455187无 PMCID | 2023-Apr-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.J Clin Oncol | PMID 36525610PMC10082249 | 2023-Apr-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.Ann Surg | PMID 36538627PMC9994847 | 2023-Apr-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer.Int J Radiat Oncol Biol Phys | PMID 36566906PMC10462387 | 2023-Apr-01 | 0.45 | The study is a Phase 3 randomized trial in oncology (prostate cancer) with a drug-related intervention (PDE5 inhibitors), but the primary efficacy endpoint is erectile function preservation, not a time-to-event endpoint like OS, PFS, or DFS. The reported secondary endpoint 'freedom from biochemical failure' is a time-to-event outcome, but it is not designated as the primary or key secondary endpoint in the abstract, and the trial's main focus is on functional preservation. | 待处理 |
| Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.J Clin Oncol | PMID 36608310PMC10082299 | 2023-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.J Clin Oncol | PMID 36720083PMC10082285 | 2023-Apr-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.JAMA Oncol | PMID 36757706PMC9912165 | 2023-Apr-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 36868261无 PMCID | 2023-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.Obstet Gynecol | PMID 36897180PMC10026946 | 2023-Apr-01 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.Lancet | PMID 36924778无 PMCID | 2023-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Home Aerobic Training for Cerebellar Degenerative Diseases: a Randomized Controlled Trial.Cerebellum | PMID 35303255PMC8932090 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.J Cancer Res Clin Oncol | PMID 35482076PMC11796584 | 2023-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis.Eye (Lond) | PMID 35523860PMC10101971 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.Eur Urol | PMID 35654659无 PMCID | 2023-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial.Cannabis Cannabinoid Res | PMID 35749710无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.BJU Int | PMID 36087070无 PMCID | 2023-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.Dig Liver Dis | PMID 36115817无 PMCID | 2023-Apr | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).Esophagus | PMID 36401133PMC10024660 | 2023-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials.Am J Ophthalmol | PMID 36410471无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study.J Nucl Med | PMID 36418170PMC10071780 | 2023-Apr | 0.90 | The study is a Phase III randomized trial in oncology (prostate cancer) with original results, but it compares two imaging radiopharmaceuticals for diagnostic accuracy, not a therapeutic drug intervention, and its primary endpoint is a detection rate (a binary outcome), not a time-to-event outcome like OS, PFS, etc. Therefore, it does not meet the required criteria for drug intervention or time-to-event endpoint. | 待处理 |
| Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers.Phytother Res | PMID 36419388无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.J Pediatr Urol | PMID 36504158无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.Transplant Cell Ther | PMID 36526260PMC10189888 | 2023-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.J Allergy Clin Immunol Pract | PMID 36535524无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Maintenance therapy in multiple myeloma: Two is not always better than one.Br J Haematol | PMID 36541138无 PMCID | 2023-Apr | 0.80 | The record is a commentary on the original phase III trial (Jenner et al.). It does not contain the primary formal results with explicit time-to-event endpoint data (e.g., OS, PFS, Kaplan-Meier, HR). Therefore, it is not eligible as an original result report for KM digitization. The 'is_eligible' criterion is set to null because the metadata cannot establish the presence of the required time-to-event endpoint in this specific document. | 待处理 |
| The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.Br J Haematol | PMID 36541152PMC10952726 | 2023-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial.Clin Transl Sci | PMID 36564964PMC10087073 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.Eur J Neurol | PMID 36583633无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).J Neurol | PMID 36598575PMC10025199 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.Clin Pharmacol Ther | PMID 36606735无 PMCID | 2023-Apr | 0.85 | The record is a methodological study that emulates a previously completed Phase III trial (CheckMate-057). It is not an original report of a drug's efficacy from a randomized trial. While it references a trial with drug intervention and time-to-event endpoints, this publication itself does not present primary or secondary results for a drug intervention in a trial. It is excluded as a non-original result report and protocol/methodology-focused study. | 待处理 |
| A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects.Clin Pharmacol Drug Dev | PMID 36648126无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial.J Bone Miner Res | PMID 36661855无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.J Hepatol | PMID 36681160无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.Clin Genitourin Cancer | PMID 36697317无 PMCID | 2023-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| First bovine vaccine to prevent human schistosomiasis - a cluster randomised Phase 3 clinical trial.Int J Infect Dis | PMID 36736992无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.Clin Oncol (R Coll Radiol) | PMID 36737311无 PMCID | 2023-Apr | 0.85 | The study is an eligible Phase III randomized oncology trial with time-to-event endpoints, but it compares two non-drug interventions (brachytherapy vs. radical prostatectomy). As no drug-containing intervention is present, it does not meet the full eligibility criteria for this cohort. | 待处理 |
| Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.Br J Haematol | PMID 36740991无 PMCID | 2023-Apr | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.Adv Ther | PMID 36749544PMC10070224 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.Br J Cancer | PMID 36759720PMC10070417 | 2023-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effects of preoperative magnetic resonance image on survival rates and surgical planning in breast cancer conservative surgery: randomized controlled trial (BREAST-MRI trial).Breast Cancer Res Treat | PMID 36786946PMC10036439 | 2023-Apr | 0.95 | The trial is a Phase III randomized controlled trial in human breast cancer with time-to-event endpoints (LRFS, OS). However, it does not meet the 'drug-containing intervention' requirement as the intervention is preoperative MRI, not a drug. Therefore, it is ineligible. | 待处理 |
| Macroscopic and multiple metastases in sentinel lymph node biopsy are respectively associated with poor prognosis in early oral cancer.Int J Clin Oncol | PMID 36795281无 PMCID | 2023-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.Lancet Gastroenterol Hepatol | PMID 36801007无 PMCID | 2023-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial.Dig Liver Dis | PMID 36804053无 PMCID | 2023-Apr | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.Lung Cancer | PMID 36806898无 PMCID | 2023-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |